These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33373114)

  • 61. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
    Chiu SM; Kuo YH; Wang JH; Hung CH; Hu TH; Lu SN; Chen CH
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2989-2997.e3. PubMed ID: 32353534
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.
    van Bömmel F; Berg T
    Liver Int; 2018 Feb; 38 Suppl 1():90-96. PubMed ID: 29427489
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients].
    Yu SL; Guo CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):267-70. PubMed ID: 24021787
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessation.
    Yang SY; Hu TH; Chou YP; Kuo YH; Tsai MC; Chang KC; Yen YH; Tseng PL
    J Infect Public Health; 2023 Nov; 16(11):1852-1859. PubMed ID: 37837921
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B.
    van Bömmel F; Berg T
    Hepatol Commun; 2021 Oct; 5(10):1632-1648. PubMed ID: 34558833
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice.
    Cuenca-Gómez JÁ; Lozano-Serrano AB; Cabezas-Fernández MT; Soriano-Pérez MJ; Vázquez-Villegas J; Estévez-Escobar M; Cabeza-Barrera I; Salas-Coronas J
    BMC Infect Dis; 2018 Nov; 18(1):568. PubMed ID: 30428845
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
    Ma TL; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
    PLoS One; 2019; 14(10):e0222221. PubMed ID: 31584951
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.
    Lee HA; Seo YS; Park SW; Park SJ; Kim TH; Suh SJ; Jung YK; Kim JH; An H; Yim HJ; Yeon JE; Byun KS; Um SH
    Clin Mol Hepatol; 2016 Sep; 22(3):382-389. PubMed ID: 27729633
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Predictors of Nucleos(t)ide Analogues Discontinuation Relapse: Hepatitis B Virus RNA versus Hepatitis B Surface Antigen.
    Wu S; Li T; Liu F; Yin D; Zhang L; Wang L
    J Coll Physicians Surg Pak; 2024 May; 34(5):545-550. PubMed ID: 38720214
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
    Tseng TN; Jeng WJ; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
    J Antimicrob Chemother; 2023 Feb; 78(2):436-439. PubMed ID: 36478233
    [TBL] [Abstract][Full Text] [Related]  

  • 73. HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
    Stelma F; van der Ree MH; Jansen L; Peters MW; Janssen HLA; Zaaijer HL; Takkenberg RB; Reesink HW
    J Viral Hepat; 2017 Dec; 24(12):1107-1113. PubMed ID: 28632898
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.
    Hung CH; Wang JH; Lu SN; Hu TH; Lee CM; Chen CH
    J Viral Hepat; 2017 Jul; 24(7):599-607. PubMed ID: 28130815
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
    Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
    Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Predictive Value of HBsAg for Off-treatment Response in HBeAg-negative Chronic Hepatitis B Patients.
    Fan X; Li T; Liu F; Zhang L; Yang B; Wang L
    J Coll Physicians Surg Pak; 2023 Jan; 33(1):47-52. PubMed ID: 36597235
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.
    Zheng Z; Liao W; Liu L; Cai S; Zhu H; Yin S
    Biomed Pharmacother; 2020 Feb; 122():109698. PubMed ID: 31918272
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.
    Wong D; Littlejohn M; Edwards R; Jackson K; Revill P; Gaggar A; Kitrinos K; Subramanian M; Marcellin P; Buti-Ferret M; Janssen H; Gane E; Locarnini S; Thompson A
    Liver Int; 2018 Oct; 38(10):1760-1769. PubMed ID: 29427368
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
    Huang PY; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
    J Viral Hepat; 2021 Aug; 28(8):1141-1149. PubMed ID: 33932245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.